Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
Q9P035
UPID:
HACD3_HUMAN
Alternative names:
3-hydroxyacyl-CoA dehydratase 3; Butyrate-induced protein 1; Protein-tyrosine phosphatase-like A domain-containing protein 1
Alternative UPACC:
Q9P035; A0PJA1; B4DRF4; Q280Z3; Q6PD63; Q8IUI5; Q8NC86; Q8NCB1; Q96T12; Q9NQA7
Background:
Very-long-chain (3R)-3-hydroxyacyl-CoA dehydratase 3, also known as 3-hydroxyacyl-CoA dehydratase 3, Butyrate-induced protein 1, and Protein-tyrosine phosphatase-like A domain-containing protein 1, plays a crucial role in the elongation cycle of long-chain fatty acids. This enzyme is pivotal in the dehydration process of 3-hydroxyacyl-CoA into trans-2,3-enoyl-CoA, facilitating the production of very long-chain fatty acids (VLCFAs). These VLCFAs are essential precursors for membrane lipids and lipid mediators, indicating the enzyme's significant role in cellular processes.
Therapeutic significance:
Understanding the role of Very-long-chain (3R)-3-hydroxyacyl-CoA dehydratase 3 could open doors to potential therapeutic strategies. Its involvement in insulin receptor signaling and modulation of gene expression through Rac1-signaling pathways highlights its potential in influencing metabolic and inflammatory diseases.